STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
January 10, 2024 03:30 ET
|
Alvotech
Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within gastroenterology, dermatology, and rheumatologyAuthorization paves...
STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara
January 10, 2024 03:30 ET
|
Alvotech
Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within gastroenterology, dermatology, and rheumatology Authorization paves...
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
January 03, 2024 03:30 ET
|
Alvotech
The confirmatory clinical, safety and efficacy study for AVT06, biosimilar candidate to Eylea® (aflibercept) met its primary endpoint in patients with neovascular (wet) Age-related Macular...
Niðurstaða rannsóknar á sjúklingum sýnir sömu klínísku virkni AVT06 líftæknilyfjahliðstæðu Alvotech og Eylea
January 03, 2024 03:30 ET
|
Alvotech
Aðalendapunktur rannsóknarinnar var uppfylltur, þegar borin var saman klínísk virkni, öryggi og ónæmingarverkun AVT06 og Eylea (aflibercept) í sjúklingum með aldurstengda vota augnbotnahrörnun (AMD) ...
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
January 03, 2024 03:30 ET
|
Alvotech
The confirmatory clinical, safety and efficacy study for AVT06, biosimilar candidate to Eylea® (aflibercept) met its primary endpoint in patients with neovascular (wet) Age-related Macular...
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
November 29, 2023 04:00 ET
|
Alvotech
REYKJAVIK, Iceland, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech kynnir jákvæðar niðurstöður úr rannsókn á lyfjahvörfum AVT05, fyrirhugaðri líftæknilyfjahliðstæðu við Simponi® og Simponi Aria®
November 29, 2023 04:00 ET
|
Alvotech
Aðalendapunktar rannsóknarinnar voru uppfylltir, en henni var ætlað að bera saman lyfjahvörf, öryggi og þolanleika AVT05 og Simponi í heilbrigðum einstaklingum. Alvotech (NASDAQ: ALVO) kynnti í dag...
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
November 29, 2023 04:00 ET
|
Alvotech
The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary endpoint Alvotech (NASDAQ: ALVO), a global biotech...
Alvotech birtir uppgjör fyrir fyrstu níu mánuði ársins 2023 og kynnir helstu áfanga á liðnum ársfjórðungi
November 28, 2023 16:15 ET
|
Alvotech
Heildarsölutekjur fyrstu níu mánuði ársins jukust í 29,8 milljónir dollara, samanborið við 11,1 milljón dollara á sama tímabili í fyrraMarkaðsleyfi var veitt fyrir AVT04 í Kanada og Japan, fyrstu...
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update
November 28, 2023 16:15 ET
|
Alvotech
Product revenue for the nine months of 2023 increased to $29.8 million, compared to $11.1 million for the same period in 2022Marketing authorization was received for AVT04 in Canada and Japan, the...